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EXECUTIVE SUMMARY 
Most Australians who have hepatitis C contracted the virus through the shared use of 
drug injecting equipment.  Further, the prevalence and incidence of hepatitis C virus 
(HCV) are high among Australian injecting drug users (IDUs), around 50 to 60 percent 
and 15 percent respectively.  The task, therefore, of controlling the spread of hepatitis C 
depends largely on controlling transmission among IDUs. Although there is a 
considerable body of research describing hepatitis C epidemiology and infection risk 
factors, very little research has examined IDUs’ understanding of hepatitis C.  The aim of 
the current study, therefore, was to examine IDUs’ knowledge of hepatitis C, their 
understanding of virus transmission, the clinical markers and symptoms of the virus, and 
treatment in particular.  How IDUs prioritise hepatitis C relative to other life areas was 
also examined. 
 
A cross-sectional survey, using an interviewer administered, structured questionnaire, was 
conducted across inner-city, suburban and regional sites of New South Wales.  
Participants were recruited through advertisements at needle and syringe programs 
(NSPs), methadone clinics, and snowballing (word-of-mouth) techniques.  Participation 
was not determined by hepatitis C status. 
 
One hundred and forty nine IDUs were interviewed.  The median age of the sample was 
34 years and approximately two-thirds were male. The median age of first drug injection 
was 17 years, with the most commonly reported illicit drugs injected in the last month 
being amphetamine (62%) and heroin (61%).  Over half of the sample (62%) was in 
treatment for drug use at the time of interview, with the majority in a methadone or 
buprenorphine program.  Over half the sample rated their knowledge and understanding 
of hepatitis C as either ‘good’ (30%) or ‘very good’ (23%).   
  
Testing for hepatitis C was common among the sample, with all but one participant 
tested for hepatitis C in their lifetime, and the majority (74%) tested one or more times in 
the past 12 months.  ‘Routine screening’ was the main reason selected for their last test 
(39%), followed by ‘mandatory testing’ (13%) and then ‘risky behaviour’ (12%).  Seventy-
six percent of the sample believed they had hepatitis C at the time of interview.  Despite 
most participants reporting recent and often multiple testing, a number of IDUs were 
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clearly confused about the results of the various tests.  Only about 40 percent of those 
tested during or after 2000 reported receiving pre- and post-test counselling.         
 
Significant gaps in IDUs’ knowledge of hepatitis C were uncovered in the study, with 
respect to transmission risks, symptoms, clinical markers and treatment.  For instance, 
substantial proportions of participants believed it was possible to contract hepatitis C by 
re-using their own needle (48%), or from dirt (17%). Forty-two percent of participants 
believed antibodies to hepatitis C gave protection against acquiring the virus (42%), and 
over one-third (35%) believed that some people are immune to hepatitis C.  IDUs’ 
understanding of their own hepatitis C infection was similarly confused, with one in five 
participants who reported having hepatitis C believing they could not infect others 
(19%), and that they were immune to hepatitis C (19%).  One in three participants stated 
they did not have antibodies for hepatitis C, and an even greater number were unsure, 
despite reporting themselves to have hepatitis C.   
  
Very few IDUs were found to prioritise hepatitis C highly relative to other life areas.  For 
many IDUs, hepatitis C appears to be a relatively low priority compared with the 
numerous health, welfare and social concerns that exist among this often economically 
and socially marginalised group.  However, health was frequently selected as one of the 
most important life areas determining quality of life, which may incorporate symptoms 
and sequelae resulting from hepatitis C impacting on day-to-day life.  
 
Given the high prevalence and incidence of hepatitis C among Australian IDUs, and that 
many continue to share injecting equipment, the findings of this study are of great 
concern.  The fundamental misconceptions held about hepatitis C, particularly regarding     
‘antibodies’  and their perceived role in providing immunity, place IDUs at serious risk of 
transmitting and contracting hepatitis C.  These findings warrant further development of, 
and research into, strategies to improve IDUs’ understanding of hepatitis C.    
 xiv
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1 INTRODUCTION 
1.1 Background 
The hepatitis C virus (HCV) was first identified in 1989 (Choo et al., 1989) and scheduled 
as a notifiable disease in Australia in 1990 (National Health and Medical Research 
Council, 1997).  It has since emerged as one of the most frequently notified diseases in 
Australia (National Health and Medical Research Council, 1997) and poses a major 
public health challenge, both in Australia and globally (Kaldor et al., 2000). 
 
The high prevalence and incidence of hepatitis C continue to result in large numbers of 
chronically ill people.  At least half of those infected will go on to experience liver disease 
and, after approximately 20 years of infection seven percent will develop cirrhosis, and 
after 40 years of infection 20 percent will develop cirrhosis.  Corresponding rates of 
mortality are one percent after 20 years and four percent after 40 years of infection (Dore 
et al., 2002).  Hepatitis C has been implicated in the increasing rate of liver cancer in 
Australia (Law et al., 2000) and is the leading cause of end-stage liver disease (Kim, 2002).   
 
Worldwide, approximately 170 million people are estimated to have chronic hepatitis C 
infection and there are three to four million new infections each year (World Health 
Organization, 2000).  In Australia, an estimated 210,000 people were living with hepatitis 
C at the end of 2001 (Law et al., 2003), a figure which is expected to increase to between 
321,000 and 836,000 by 2020 (Hepatitis C Virus Projections Working Group, 2002).  The 
potential cumulative health care costs of hepatitis C infection over the next 60 years have 
been estimated at approximately $4 billion (Brown & Crofts, 1998). 
  
Hepatitis C is a blood-borne infection and the majority of infections occur via parenteral 
transmission (for a full discussion of transmission and risk factors see MacDonald et al., 
1996). In Australia, blood and blood products have been screened since 1990 and, 
therefore, the risk of medically acquired infection is very low (Dore et al., 2003). Other 
potential modes of infection include tattooing and body piercing, although when 
performed by professionals practicing infection control, the risk is significantly reduced. 
Household transmission via the shared use of toothbrushes and razors or other items 
where blood-to-blood exposure is possible is also a risk factor, but the actual risk of 
transmission via this mode is considered very low (Dore et al., 2003).  Although sexual 
transmission is possible, the available evidence indicates only a very small number of 
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cases are likely to have occurred via this mode in Australia (Sladden et al., 1997), and it is, 
therefore, considered low risk (Dore et al., 2003).  
 
 It is the shared use of injecting equipment by injecting drug users (IDUs) that is by far 
the most common mode of hepatitis C transmission in Australia, and this practice poses 
an extremely high risk of infection.  According to national surveillance data, the 
proportion attributable to drug injection is approximately 90 percent (National Centre in 
HIV Epidemiology and Clinical Research, 2002).  The task, therefore, of controlling the 
spread of hepatitis C depends largely on controlling transmission among IDUs (Crofts & 
Aitken, 1997).  While prevention initiatives such as needle and syringe programs (NSPs) 
and methadone maintenance treatment have helped to maintain low prevalence and 
incidence of HIV among Australian IDUs, they have been less effective in stopping the 
spread of hepatitis C, which was already prevalent prior to the introduction and 
expansion of these programs (Dore et al., 2003).   
 
1.2 Prevalence of hepatitis C among injecting drug users  
Hepatitis C is the most prevalent blood-borne viral infection (BBVI) among Australian 
IDUs.  The prevalence of hepatitis C among Australian IDUs has been continually high 
since the mid 1970s, estimated to be between 63% and 50% among needle and syringe 
programs attendees from 1995 to 1997 (MacDonald et al., 2000) and 54% in 2000 to 
60% in 2004 (National Centre in HIV Epidemiology and Clinical Research, 2005). 
 
1.3 Incidence of hepatitis C among injecting drug users 
The incidence of hepatitis C is also high.  Crofts and Aitken (1997) reported an incidence 
of 11 per 100 person years among a cohort of Victorian IDUs.  Van Beek and colleagues 
(1998) reported an even higher incidence of 21 per 100 person years among young IDU 
clients attending a primary health care centre.  Dolan et al. (2003) has reported a very 
high hepatitis C incidence of between 24 and 48 per 100 person years for prisoners, 
depending on whether they were in methadone treatment or not.  More recently, Maher 
et al. (in press) reported an incidence of 30.8 per 100 person years among IDUs in South 
West Sydney.  According to the Hepatitis C Estimates and Projections Working Group, 
the estimated annual incidence of hepatitis C is approximately 15% (Law et al., 2003). 
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1.4 Injecting drug users’ knowledge of hepatitis C 
The risk factors associated with hepatitis C infection among IDUs are relatively well 
established and include needle and syringe sharing, the sharing of injecting paraphernalia 
such as spoons, water and filters (known as ‘indirect’ sharing), incarceration, age, sex, 
ethnicity, length of injecting career and frequency of injecting, the injection of opiates 
and injecting practices and environments.  Although there has been a plethora of 
research describing hepatitis C epidemiology and infection risk factors (for a review see 
Hocking et al., 2001), very few studies have examined IDUs’ understanding of hepatitis 
C.  This includes the way IDUs interpret the medical terms, clinical markers and 
symptoms associated with hepatitis C, the perceived risks of transmission, and their 
knowledge and experience of treatment.   
 
Subsequent to acquiring hepatitis C, a person will produce hepatitis C antibodies. 
However, approximately a quarter of those initially infected with hepatitis C clear the 
virus, so not all those with hepatitis C antibodies are actually infected (or infectious), but 
anyone who has been infected (i.e. exposed), irrespective of whether or not they have 
cleared the virus, will have hepatitis C antibodies. Yet most diagnoses occur using only 
hepatitis C antibody testing, a polymerase chain reaction (PCR) test (testing for viral 
RNA) is required to determine viremia; it is only with this test that a person will know 
their actual status.  
 
There is currently no vaccination against hepatitis C and no one is immune, including 
those who have had prior exposure and have since cleared the virus. This is in contrast to 
hepatitis B, where prior infection affords lifelong immunity (accept in cases of chronic 
infection, which occurs in about 5% of cases). All people actually infected with hepatitis 
C (but not simply those with antibodies), therefore, have the potential to pass on the 
virus. It is these issues which potentially cause confusion and, albeit limited, there is 
evidence that this may be the case.  
 
One qualitative study involving 59 IDUs in London found there was much confusion 
and uncertainty surrounding hepatitis C, including its medical and transmission risks 
(Rhodes et al., 2004).  Participants expressed confusion over the differences between 
various forms of hepatitis virus, the symptoms of hepatitis C, and said that they lacked 
knowledge about potential transmission risks associated with sharing injecting 
paraphernalia.  Further, communication of hepatitis C testing and diagnosis was reported 
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as poor, leaving many injectors confused or anxious as to the meaning and implications 
of their antibody status.  Australian research has also found that IDUs presenting for 
hepatitis C testing often report receiving inadequate, or no, pre- and post-test counselling 
(Loxley et al., 2000), although there is some evidence of increasing dissemination of 
hepatitis C information by doctors at diagnosis (Hopwood & Treloar, 2003).      
 
A North American study (Heimer et al., 2002) comparing HIV and hepatitis (B and C) 
knowledge found that, although IDUs were well aware of the nature, effects and 
consequences of HIV infection, they were ill-informed about hepatitis and hepatitis risk.  
The 493 inner-city IDUs surveyed for this study were almost three times more likely to 
respond ‘don’t know’ to items assessing knowledge of hepatitis compared to HIV 
pertaining to routes of infection, detection of disease, viability of the organism within 
ambient environments, potential treatment and prevention measures.   
 
Similarly, recent qualitative research conducted in Australia on the risks of injecting 
revealed that IDUs had a poor understanding of what it means to have hepatitis C 
infection (Southgate & Weatherall, 2003; Southgate et al., 2005).  The IDUs were unclear 
about what it meant to have ‘antibodies’, with many participants believing this meant 
they had cleared the virus and, therefore, were no longer infectious.  There was also 
noted confusion around the symptoms related to hepatitis C, and confusion with other 
BBVI and hepatitis viruses.  For example: a number of IDUs believed that if they do not 
suffer jaundice they have not become infected with hepatitis C.   
 
Southgate et al. (2003; 2005) found that many IDUs demonstrated a good technical 
knowledge of the transmission of hepatitis C, such as being aware of the risk of sharing 
needles and syringes.  Indeed this is supported by an overall reduction in the prevalence 
of needle sharing in Australia (Crofts et al., 1996; Crofts & Aitken, 1997; MacDonald et 
al., 2000).  However, a number of IDUs appeared to be confused and misinformed 
believing hepatitis C could be contracted from unhygienic practices such as using toilet 
water to inject or wash with or that it could be contracted from ‘dirt’.  Although highly 
informative, the limitations of this study include a small sample of IDUs (N=24) drawn 
from one, rather unique, inner-city Sydney setting (Kings Cross) and the collection of 
limited demographic and behavioural information.  Therefore, further research is 
required to determine if these findings are consistent and the issues in particular that 
cause confusion.   
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1.5 Quality of life 
Quality of life (QOL) is an important part of assessing and understanding the burden of 
disease and planning policy and evaluation (Brogly et al., 2003b; Muldoon et al., 1998).  
Although the definition of QOL is debated, there is consensus that QOL pertains to 
physical, psychological, and social functioning, and more recently that it includes abilities, 
relationships, perceptions, life satisfaction, and wellbeing (Berzon et al., 1993; 
Dauphinee, 1999). 
 
Hepatitis C has been found to reduce health-related QOL (Foster, 2004; Thein et al., 
2005) and is, therefore, likely to have an impact on overall QOL.  IDUs face a number of 
complex health, welfare and social problems and despite the very high prevalence and 
incidence of hepatitis C among IDUs, it is just one of these many problems.  Yet, there is 
currently little understanding of how IDUs prioritise hepatitis C relative to other life 
areas.   
 
The Injection Drug User Quality of Life Scale (IDUQOL) was designed to measure 
QOL in IDU populations (Brogly et al., 2003b).  The IDUQOL uses a subjective 
approach and, unlike most standardised QOL measures, allows for the individual to 
select the aspects that construct their QOL and to weight the importance of each aspect 
(Brogly et al., 2003b).  It is therefore an ideal instrument to assess both quality of life 
among IDUs and also how hepatitis C is prioritised.  
 
1.6 Study aims 
In summary, there is a paucity of research describing IDUs’ knowledge of hepatitis C and 
perception of transmission risks, although existing studies suggest that there may be 
significant gaps in their knowledge.  A lack of knowledge of hepatitis C will prevent 
IDUs from implementing measures that could reduce their risk of contracting the virus 
and increase the likelihood of transmission to others.  As noted by Southgate et al. 
(2005), IDUs “take up the clinical language of medicine and health promotion and 
actively use it to make sense of living with HCV and to assess the likelihood of infecting 
others”.  
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The current study was undertaken to assess IDUs’ understanding of hepatitis C using a 
quantitative approach and a sample drawn from inner-city, as well as suburban and 
regional settings.  Specifically, the study aimed to examine IDUs’ knowledge and 
understanding of: 
 
1) hepatitis C transmission; 
2) the symptoms and clinical markers of hepatitis C; and 
3) hepatitis C testing and treatment. 
 
The study also aimed to examine quality of life and how IDUs prioritise hepatitis C 
relative to other life areas using the IDUQOL. 
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2 METHODS 
2.1 Participants and recruitment 
Injecting drug users (IDUs) drawn from four sites, inner-city (Surry Hills, Sydney, NSW), 
outer metropolitan/suburban (Blacktown and Parramatta, Sydney, NSW) and regional 
NSW (Newcastle, NSW) were invited to participate in the research.   
 
Participants were recruited through advertisements at needle and syringe programs 
(NSPs), methadone clinics, and snowballing (word-of-mouth).  IDUs who reported 
injecting drug use at least once per month during the past six months, were aged 18 years 
or more and fluent English speakers were eligible.  Participation was not determined by 
hepatitis C status (actual or perceived). 
   
2.2 Instrument 
A questionnaire was purposefully designed and pilot tested to obtain demographic 
information, drug use and treatment history, injecting behaviour and details of BBVI test 
history.    
 
A series of questions examined IDUs’ knowledge of hepatitis C and their understanding 
of having the virus including that of clinical terms and symptoms.  Topic areas covered 
included blood-borne viral infection risks (based on the Opiate Treatment Index, Darke 
et al., 1991), sources of information used and experience of hepatitis C testing and 
treatment (where applicable).  A series of true/false statements were also devised to elicit 
participants’ beliefs about relative risks of transmission and their understanding of 
clinical markers and treatment. 
 
An adapted form of the IDUQOL (Brogly et al., 2003b)  was used to assess QOL, with 
the life area card ‘Cure for AIDS’ replaced with a card representing ‘Hepatitis C’.  This 
was done because a) the prevalence of HIV is low among Australian IDU (MacDonald et 
al., 1997; National Centre in HIV Epidemiology and Clinical Research, 2005) and, 
therefore, unlikely to be selected. Conversely, given the high prevalence of hepatitis C, it 
was of interest to examine how this would be rated. The IDUQOL is interviewer 
administered and consists of titled picture cards depicting 17 life areas and a response 
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form.  The life areas are: health, housing, partnership, family, money, resources, 
education, sex, friends, drugs, drug treatment, feeling good, being useful, independence 
and free choice, leisure activities, Hepatitis C, and spirituality.  The IDUQOL has good 
psychometric properties (Brogly et al., 2003b; Brogly et al., 2003a) and has been found to 
be acceptable among Australian IDU (Kimber & Day, 2003).  The IDUQOL took 
approximately 15 minutes to complete.  
 
2.3 Procedure 
The questionnaire was piloted with participants recruited through street press (n=15) and 
found to be acceptable with only minor amendments required.  Pilot questionnaires were 
excluded from the analysis.   
 
Interviews were carried out by trained interviewers (including some peers) employed by 
the National Drug and Alcohol Research Centre between July and September 2004.  
Excluding the IDUQOL (outlined below) the interview took approximately 30 minutes 
to complete.  Referral to the NSW Hepatitis C telephone helpline was offered to all 
participants and debriefing, including appropriate and correct hepatitis C information, 
was provided at interview completion. 
 
2.3.1 Injecting Drug Users Quality of Life (IDUQOL) scale 
The IDUQOL begins by asking participants to rate their overall quality of life on a scale 
of 0 to 10, where 0 is the worst they can imagine and 10 is the best they can imagine.  
They are then asked to describe the five areas in their life that currently most determine 
their quality of life.  The participant is then shown the life area cards and asked to select 
the cards depicting their five most important areas (which may not necessarily be the 
same five areas they identified independently) and asked to describe what each of these 
means to them (life area selection).  Participants are then asked to apply a weighting to 
each of these areas by distributing 25 chips across the five cards, according to their 
relative importance, where more chips indicate a life area is more important (life area 
weighting).  Participants are then asked to rate these life areas according to how well each 
life area is progressing on a scale of 0 to 100, where 0 is the worst they can imagine and 
100 is the best they can imagine (life area rating).  In the final part of the IDUQOL, 
participants are asked once again to rate their overall QOL on a scale of 0–10.  
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2.4 Ethics 
All participants were volunteers, provided informed consent and were reimbursed A$30 
for travel and time expenses.  The reimbursement of participants is considered both 
necessary and ethical in illicit drug use research (Marsh & Loxley, 1992; McKeganey, 
2001) and has not been found to coerce participants (Fry & Dwyer, 2001) or adversely 
affect drug use or data quality (Festinger et al., 2005).  The research was approved by the 
Human Research Ethics Committees of the University of NSW and the three Area 
Health Services involved in the study (i.e. South Eastern Sydney, Western Sydney and the 
Hunter).         
 
2.5 Data analysis 
Continuous variables were assessed using t-tests.  Medians are reported where data were 
highly skewed.  The chi square (χ2) statistic was used for univariate analysis of categorical 
data. 
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3 RESULTS  
3.1 Sample characteristics 
One hundred and forty-nine IDUs were surveyed: 55 from inner-city, 56 from suburban 
and 38 from regional sites.  Demographic characteristics of the sample are shown in 
Table 3.1.  The median age of participants was 34 years and almost two thirds were male.  
The majority of the sample (89%) reported Australia as their country of birth, with the 
remainder reporting a range of countries across Europe (5%), Oceania (5%), the Middle 
East (1%) and North America (1%).  Seven percent reported being homeless or living on 
the street and a further 12% reported unstable living circumstances (i.e. in a refuge, 
hostel, shelter or squat).   
 
The majority of the sample (85%) reported being unemployed (65%) or on a pension 
(20%).  Six percent were in part time or casual employment, four percent reported that 
they were engaged in home duties, three percent in full time employment and one 
percent were students. Nine percent reported being paid for sex work in the month 
preceding interview.   
 
Educational status was varied, with a mean of 11 years completed education (including 
kindergarten, where attended).  Approximately one-third of the sample had completed a 
trade or technical qualification as their highest level of education (28%), and just over 
one-tenth had completed a university or college qualification (13%).   
 
Over half of the sample (62%) was in treatment for drug use at the time of interview, 
with the majority in a methadone or buprenorphine program.  A large proportion of the 
sample reported a prison history, and of this group, one-fifth (17% of the entire sample) 
reported last being incarcerated in 2004 (the year of interview).   
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Table 3.1: Demographic characteristics of the sample  
 Total (N=149) 
Median age (range; SD)a 34.0 years (20–52; 7.2) 
Gendera 
male 
female 
transgender 
% 
62 
36 
1 
Australian-born 89 
Aboriginal and/or Torres Strait Islander 19 
Homeless/unstable circumstances* 19 
Current drug treatment 
methadone or buprenorphine 
counselling 
other  
rehab 
not in treatment 
 
55 
3 
3 
1 
38 
Unemployed/pensioner 85 
Sex work (last month) 9 
Mean years of school completed (range; SD) 11 years (2–21; 2.0) 
Education 
 University/college qualification 
 Trade/technical qualification 
% 
13 
28 
Ever incarcerated 
last in prison in 2004 
81 
17 
a1 case missing data 
*Includes homeless/street, refuge/hostel/shelter and squat living arrangements 
 
3.2 Injecting history 
Median age of first drug injection was 17 years (Table 3.2).  The majority of the sample 
(77%) reported having injected another person, with the median number of people ever 
injected being 10 (range 1–300).  Among the 53% of the sample who reported injecting 
another person in the last 12 months, this figure reduced to a median of three people 
(range 1–100).  Thirty-nine percent of the sample had taught another person to inject, the 
median being two people (range 1–100).  Twenty percent of the sample reported 
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teaching a person to inject in the last 12 month, the median number of people being two 
(range 1–21).    
 
Table 3.2: Injecting history, injection of others and initiation of others 
 Total (N=149) 
Median age first injected (range; SD) 17 (10–38; 5.3) 
Ever injected another persona 77% 
Among those who had ever injected another person 
median number of people ever injected (range; SD) 
 
10 (1–300; 53.8) 
Among those who had injected another person in the last 12 months 
median number of people injected last 12 months (range; SD) 
 
3 (1–100; 21.8) 
Ever taught another person to injectb 39% 
Among those who had ever taught another person to inject 
median number of people ever taught to inject (range; SD) 
 
2 (1–100; 14.3)  
Among those who had ever taught another person to inject in the last 12 months 
median number of people taught to inject last 12 months (range; 
SD) 
 
2 (1–21; 5.1) 
a3 cases missing data 
b1 case missing data 
 
3.3 Lifetime and current drug use 
Data regarding drug use and injection for the most commonly injected illicit drugs in 
NSW at the time of interview are presented in Table 3.3.  The overwhelming majority of 
the sample had both used and injected heroin and amphetamine at least once in their 
lifetime, with high proportions also reporting use of methadone, cocaine and 
benzodiazepines.  A substantial proportion of the sample also reported lifetime injection 
of methadone and cocaine (68% and 62% respectively).  
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Table 3.3: Lifetime and current drug use 
Total (N=149)
 Ever used 
(%) 
Ever 
injected 
(%) 
Injected 
last 6 
months 
(%) 
Injected 
last month 
(%) 
Median no. 
injections 
last mth* 
 
Heroin 97 97 69 61 9 
Methadone 91 68 34a 28 6 
Other opioids 48 36 24 17 5 
Amphetamines 95 95 72 62 5 
Cocaine 68a 62 22 16 2 
Benzodiazepines 75 30 8 6 2 
a1 case missing data 
*Among those who had injected in the last month 
 
The most commonly reported illicit drug injected in the last month was amphetamine 
(including methamphetamine; reported by 62% of the sample) on a median of five 
occasions.  Injection of heroin was also common, with 61% of the sample reporting 
injecting heroin a median of nine times in the preceding month.  Just over one-quarter of 
the sample (28%) reported injecting methadone on a median of six occasions in the 
month prior to interview.   
 
3.4 Injecting and blood-borne virus risk 
In the last month, the majority of participants had injected at home (79%) or a friend’s 
place (42%).  Other injecting locations included streets, parks or benches (35%), public 
toilets (32%), cars (22%) and the Sydney Medically Supervised Injecting Centre (16%).   
 
Over half the sample (52%) reported that they had re-used their own needle in the last 
month, with 26% doing so three or more times.  Most of these participants (85%) 
reported that they had not cleaned the re-used syringe with bleach on any of these 
occasions.  Sixteen participants (11%) reported using a syringe after another person in 
the last month, virtually all of whom also reported never cleaning the syringe with bleach 
during that time.  Twenty-one percent of the sample had been injected by another person 
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in the last month, with half of these participants stating this had occurred more than five 
times.    
 
A substantial proportion of the sample reported using injecting equipment after another 
person in the past month: 40% a spoon, 35% a drug solution/mix, 33% water, 29% a 
filter and 12% a tourniquet.   
 
As described previously (Table 3.1), 81% (n=120) of the sample reported that they had 
been incarcerated in the past.  Of these, approximately one quarter (22%) had received a 
tattoo, nearly half (44%) had injected and one-third had shared a syringe while in prison 
(Table 3.4).  Among those who reported injecting in prison, the proportion who had 
shared a syringe was high (75%).    
 
Table 3.4: Blood-borne virus risk behaviours in prison 
 n=120 
Ever received a tattoo in prison 22% (n=26) 
Ever injected in prison 44% (n=53) 
Ever shared a syringe in prison 
of those who had injected in prison, % who shared a syringe 
33% (n=40) 
75% 
 
 
3.5 Hepatitis C, hepatitis B and HIV testing 
According to self-report, almost all participants had been tested for a BBVI (HBV 87%, 
HIV 97% and HCV 99%).  Among those who reported being tested, the median number 
of weeks since their last test was 26 weeks for hepatitis B (range < 1–1040), HIV (range 
< 1–728) and hepatitis C (range < 1–520).  Eighteen percent of those tested reported 
having HBV, although there was some confusion around HBV status.  Fifty-three 
percent of the sample reported being vaccinated against HBV (42% fully and 11% 
partially).  Based on the results of their last test, seven participants (5%) believed that 
they were HIV positive.         
 
Only one participant reported never being tested for hepatitis C.  Of those who were 
tested, based on the results of their last test, 74% responded they had hepatitis C, four 
percent that they had hepatitis C in the past but no longer, and five percent ‘other’ (e.g. 
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“have hep C but it is inactive”, “I have the virus but I’m not infectious”, “didn’t get 
result”).  General practice clinics were the most commonly reported setting of the most 
recent test (Figure 3.1).  Based on participants’ recollection of the testing, 38% of those 
tested during, or after, 2000 reported receiving pre-test counselling (62% reported that 
they had not received pre-test counselling and one percent reported being unable to 
remember).  Similarly, 39% reported post-test counselling (58% reported that they had 
not received post-test counselling and one percent each could not remember, did not 
pick up the results and were due to pick up the results).  It should be noted that in order 
to minimise confusion about the term ‘counselling’ in the context of hepatitis C testing 
(rather than drug and alcohol, mental health or other forms of psychological counselling), 
participants were asked “The last time you were tested, did a doctor or other professional 
discuss hepatitis C, the test and the meaning of the test before you had it (pre-test 
counselling)?” and “The last time you were tested, did a doctor or other professional 
discuss hep C, the test and the results with you after you had it (post-test counselling)?”. 
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Figure 3.1: Setting of last hepatitis C test 
 
3.6 Reasons for hepatitis C testing 
Among the 148 participants tested for hepatitis C, ‘routine screening’ was the main 
reason selected for their last test (39%), followed by ‘mandatory testing’ (13%) and ‘risky 
behaviour’ (12%) (Figure 3.2).  Fourteen percent of participants reported other varied 
reasons, including being tested when pregnant, following needle stick injuries, general 
concern and curiosity.  It should be noted that ‘mandatory testing’ in this study refers to 
participants perception of the testing, rather than testing as required by law or policy. 
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The reason given by the one participant who had never been tested was that they 
“haven’t got around to it”.  Participants who believed they had never tested positive for 
hepatitis C reported the main reasons they would get tested again as ‘risky behaviour’ 
(62%), ‘routine screening’ (38%) and ‘partner/friend diagnosed with hepatitis C’ (19%).  
Less commonly selected reasons were ‘Hep C symptoms’ (10%), ‘feeling unwell’ (10%) 
and ‘doctor/other health professional recommendation’ (10%).    
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Figure 3.2: Primary reason for hepatitis C testing   
 
3.7 Hepatitis C symptoms prior to testing 
When asked whether they had experienced any signs of hepatitis C infection prior to 
testing, 31% of participants reported they had (n=46).  The most commonly reported 
symptoms among this sub-sample were lethargy (70%), followed by feeling unwell (43%) 
and nausea (37%) (Figure 3.3).  Seventeen percent reported jaundice like symptoms 
(yellowing of the eyes or skin) prior to testing.  A range of other signs of infection were 
reported by over one third of participants, many of which could be generally categorised 
as liver pain (e.g. ‘tender liver, liver pains’) and depression related (e.g. ‘feeling down and 
unmotivated’).  
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Figure 3.3: Symptoms experienced prior to hepatitis C testing  
 
3.8 Hepatitis C knowledge (self-rating) 
Participants were asked to rate their knowledge/understanding of hepatitis C on a scale 
of 1–5 (excellent = 1; poor = 5).  Half the sample rated their knowledge as either ‘good’ 
(30%) or ‘very good’ (23%), and 15% rated their knowledge as ‘poor’ (Figure 3.4). 
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Figure 3.4: Participants’ rating of their knowledge of hepatitis C 
 
 
3.9 Hepatitis C understanding  
A series of detailed questions concerning participants’ hepatitis C status was asked in 
order to elicit their understanding of their infection.  Seventy-six percent of the sample 
believed they had hepatitis C at the time of the survey (‘do you have hepatitis C?’), with a 
further four percent unsure of their status.  Of the twenty-nine participants (20%) who 
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believed they did not have hepatitis C, five (17%) believed themselves to have previously 
been infected.  
 
When participants who believed they were infected with hepatitis C were asked if they 
had antibodies for hepatitis C, only 31% responded that they did, and a further 40% were 
unsure.  Twenty-eight percent believed that they did not have hepatitis C antibodies.  
Only one participant, who believed they had never been infected with hepatitis C, also 
believed that he had hepatitis C antibodies.  One participant reported they did not have 
hepatitis C presently, but had in the past, and now had hepatitis C antibodies.     
 
Of the 113 participants who believed they had hepatitis C, 19% thought that they could 
not pass it on to others.  One participant reported “I can't pass it on, ‘cause I have a 
good liver”.  A further 13% were unsure whether or not they could.  
 
Nineteen percent of those who reported having hepatitis C believed that they were 
immune to hepatitis C and 23% were uncertain.  Of the 29 participants who reported 
that they were not infected with hepatitis C, only one believed herself to be immune, 
because “I’m a carrier, but I don't have the disease”.  A further six were unsure whether 
or not they were ‘immune’ (21%).   
 
When participants were asked how they came to their understanding of their hepatitis C 
status, 78% of those tested stated that they were informed by the diagnosing doctor.  
Other primary sources of information used by participants included the diagnosing 
health professional (other than a doctor) (7%), reading and self education (5%), 
organisations (5%, mainly prison), medical specialists (3%), friends (1%) and others with 
hepatitis C (0.7%). 
 
Some of the key findings pertaining to participants’ understanding of their hepatitis C 
status, infectiousness and immunity have been summarised in Table 3.5.    
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Table 3.5: Participants’ perception of hepatitis C status, infectiousness and 
immunity 
 % 
Those who believed they were infected with hepatitis C, 
but not infectious  
 
19 
Those who believed they were infected with hepatitis C, 
but uncertain whether they were infectious 
 
13 
Those who believed they were infected with hepatitis C, 
but immune to hepatitis C  
 
19 
Those who believed they were infected with hepatitis C, 
but did not have antibodies  
 
28 
Those who believed they were infected with hepatitis C, 
but uncertain whether they had antibodies  
 
40 
 
 
3.10 Hepatitis C knowledge 
A series of true/false/don’t know statements were devised to elicit participants’ 
knowledge about hepatitis C, including the relative risks of transmission, clinical markers 
and treatment.   
 
3.10.1 Risks of transmission 
As shown in Table 3.6, substantial proportions of the sample held incorrect beliefs or 
were unclear about various aspects of hepatitis C transmission.  Although the vast 
majority of the sample (96%) knew that injecting drugs carried a high risk of hepatitis C 
transmission, close to half of the sample (48%) believed it was possible to acquire 
hepatitis C from reusing their own needle that no-one else had used.  Many participants 
were also confused about the risk of hepatitis C transmission involved in sharing 
household items such as toothbrushes or razors, with approximately 80% failing to 
endorse the statement that the risk is low.  Similarly, more than half of the sample (59%) 
believed incorrectly that unprotected sex with hepatitis C positive persons was a high risk 
activity in terms of hepatitis C transmission.  Just under half of the sample (44%) 
believed that hepatitis C positive mothers are at high risk of transmitting hepatitis C to 
their child through pregnancy, childbirth and breastfeeding, and approximately one third 
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(28%) did not know that this, in fact, was low risk.  A substantial minority of participants 
(17%) thought it was possible to contract hepatitis C from dirt and a further 28% were 
unsure whether it could be acquired from dirt or not.      
 
3.10.2 Clinical markers  
There was also some uncertainty relating to the clinical markers of hepatitis C, primarily 
with regard to participants’ understanding of antibodies and immunity (Table 3.6).  
Although most of the sample answered correctly that people with hepatitis C antibodies 
can infect other people with hepatitis C (73%), many thought that antibodies to hepatitis 
C also gave protection against acquiring the virus (42%).  Over one-third of the sample 
(35%) wrongly believed that some people are immune to hepatitis C and a further 20% 
were unsure.  Approximately one-quarter of the sample (26%) mistakenly believed that 
hepatitis C was always associated with jaundice, and a further 13% were unsure.  
However, most of the sample answered correctly that there was more than one hepatitis 
C strain (85%) and that in some cases the virus naturally clears (71%).  Similarly, the 
majority answered correctly that a normal liver function test result was not an indication 
of hepatitis C negativity (76%) or infectiousness (77%) and that once cleared, hepatitis C 
can be acquired again (75%).  
 
3.10.3 Treatment 
Although the majority of the sample knew that there is medical treatment available for 
hepatitis C (77%), many were confused about herbal treatments, reporting uncertainty as 
to whether they could cure hepatitis C (34%), or wrongly believing that they could (15%).  
There was also confusion surrounding infectiousness after successful medical treatment 
with Interferon, with approximately one third (32%) believing it was still possible to pass 
on the virus and over one third (41%) unsure.  
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Table 3.6: Participants’ knowledge of hepatitis C 
 Total (N=148) 
Statements* Incorrect 
answer 
 (%) 
Don’t 
know 
(%) 
Risks of transmission:   
People who have unprotected sex with hepatitis C 
positive people are at high risk for hepatitis C (false–low 
risk) 
59 4 
People who have close contact with someone who has 
hepatitis C are at very low risk for hepatitis C (e.g. 
hugging, kissing and sharing household items such as 
cups or forks) (false–no risk) 
41 1 
People who share household items such as toothbrushes 
or razors are at low risk for hepatitis C (true) 
79 1 
People who inject drugs are at high risk for hepatitis C 
(true) 
3 1 
People who get tattoos or body piercing are at high risk 
for hepatitis C (false–medium to low risk^) 
17 6 
Hepatitis C positive mothers are at high risk of 
transmitting hepatitis C to their child through pregnancy, 
childbirth and breastfeedinga (false–low risk) 
44 28 
It is possible to contract hepatitis C from reusing your 
own fit that no-one else has used (false) 
48 15 
It is possible to contract hepatitis C from dirt (false) 17 28 
*Correct answer in parentheses. Based on information derived from Australian Government Department 
of Health and Ageing and the Australian Institute of Primary Care (2001) and the Hepatitis C Council of 
New South Wales (2001).  
^It was explicitly stated to participants that the survey item referred to tattooing and body piercing in 
general.  By contrast, unsterile tattooing and piercing by someone who is hepatitis C positive is considered high risk 
for transmission 
a2 cases missing data 
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 Total (N=148) 
Statements* Incorrect 
answer 
(%) 
Don’t 
know 
(%) 
Clinical markers:   
All people with hepatitis C get jaundice (go yellow) (false) 26 13 
Some people naturally clear the hepatitis C virus (true) 14 15 
Antibodies to hepatitis C give you protection against 
contracting the virus (false) 
 
42 
 
24 
People with hepatitis C antibodies can infect other people 
with hepatitis C (true) 
 
9 
 
18 
If a person’s Liver Function Tests are fine they do not have 
hepatitis C (false) 
 
16 
 
8 
If a person’s Liver Function Tests are fine they can no 
longer pass hepatitis C on to other people (false) 
 
9 
 
14 
There is more than one kind of hepatitis C (true) 7 8 
People who have cleared the hepatitis C virus cannot 
contract it again (false) 
 
10 
 
15 
Some people are immune to hepatitis C (false) 35 20 
Treatment:   
There is a medical treatment for hepatitis C (true) 14 9 
Herbal remedies can cure hepatitis C (false) 15 34 
A person who has been treated with Interferon and has 
cleared the virus can infect other people with hepatitis C 
(false) 
 
32 
 
41 
*Correct answer in parentheses, based on information derived from Australian Government Department 
of Health and Ageing and the Australian Institute of Primary Care (2001) and the Hepatitis C Council of 
New South Wales (2001). 
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3.11 Hepatitis C testing experience and understanding of results 
Diagnostic testing was common among the sample, with the majority (74%) reporting 
one or more of five different tests in the past 12 months.  Hepatitis C antibody testing 
was the most common (64%), followed by the alanine aminotransferase test (ALT)/liver 
function test (LFT) (50%), PCR (12%), liver ultrasound (10%) and the liver biopsy test 
(3%).   
 
Participants who had reported undergoing diagnostic testing in the last 12 months were 
asked open ended questions about the result and meaning of their tests.  Two-thirds of 
participants who had a hepatitis C antibody test in the past 12 months responded that the 
results of that test were ‘positive’, ‘positive for antibodies’ or ‘antibodies present’ (66%).  
However, some were unsure or confused about what these results meant in terms of 
their prognosis or their ability to infect others.  For example, statements regarding their 
test results included: “I've had an exposure, but can't pass it on because I have 
antibodies” (self-reported test result: “positive”); “It means I'm going to get sick” (self-
reported test result: ‘positive’); “I’m diseased and should stay away from clean people” 
(self-reported test result: ‘positive’); “I’m not sure….I have the virus?” (self-reported test 
result: ‘positive’); and “It's dominant in myself, but I can't pass it on to anyone else” (self-
reported test result: ‘Hep C negative, but positive for antibodies’).  Some appeared to use 
the term ‘antibodies’ to describe having a resistance to hepatitis C, for example: “I’ve 
built up antibodies, so my liver won't be affected” (self-reported test result: ‘negative’).  
One participant believed the virus was “dormant” despite having antibodies (self-
reported test result: ‘antibodies present’).    
 
Over one quarter (26%) of those undergoing an ALT/LFT reported that they did not 
know the results of that test.  One participant stated about their ALT/LFT result, “the 
doctor told me, but it didn’t make sense”.  An even greater proportion (66%) of those 
undergoing a PCR test did not know, or remember, the result.  Three of the 15 
participants (20%) who reported having a liver ultrasound in the past 12 months also 
reported not knowing the result of that test.     
 
Of the 113 participants who believed they had hepatitis C, 20% reported that they had 
seen a gastroenterologist or other liver specialist for hepatitis C in the past.  Sixteen 
percent had tried herbal remedies (e.g. St Johns Wort), 14% had tried complementary 
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therapies (e.g. acupuncture, massage) and three percent had received 
Interferon/Ribavirin treatment.    
 
When participants who believed they had hepatitis C were asked how severe they 
thought their infection, the majority rated it as mild (50%) or moderate (22%).  A further 
11% of participants responded that they “didn’t know”, nine percent “quite bad” and six 
percent “very bad”.  Participants were then asked whether they based this opinion on 
their symptoms (or lack thereof), their test results (as advised by clinician), or otherwise.  
More participants based their opinion on their symptoms (or lack of) (67%) rather than 
their test results (20%).  Other responses included, “[very bad, based on] my age, it just 
has to be bad” (1%), “[moderate, based on] the fact I can’t give it to other people” (1%), 
“[moderate, based on] colour of urine and faeces” (1%), “[mild], compared to other 
people I know who have it” (1%), “[mild, based on] both clinical markers and 
symptoms” (1%).     
  
3.12 Hepatitis C information and advice 
All participants were asked where they got their information about hepatitis C.  Leaflets 
and other written material (e.g. from NSPs, GPs) provided the main sources of 
information about hepatitis C, with 60% of the sample naming this option.  Also selected 
by approximately one-quarter or more of the sample as main sources of information 
were GPs (verbal information; 45%), user organisation publications (e.g. Users News, 
Junk Mail; 32%), friends /family /partners /other users (32%), drug treatment services 
(24%) and NSPs (verbal information; 23%) (Figure 3.5 and Table 3.7).  Eighteen percent 
of the sample identified other various main sources of information (e.g. TAFE, medical 
textbooks, the newspaper).  The most commonly reported ‘other’ main source of 
information about hepatitis C was prison, reported by nine percent of the sample.     
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Figure 3.5: Sources of information about hepatitis C  
 
When asked to select one main source of information, leaflets and other written material 
were used the most (24%), followed by GPs (18%) and friends /family /partners /other 
users (11%) (Table 3.7).    
 
Overall, the majority of the sample reported that they were ‘very confident’ (48%) or 
‘confident’ (35%) with the credibility of their main source of information in terms of 
providing accurate knowledge and explanation of hepatitis C.  Fourteen percent and two 
percent of the sample respectively, reported that they were ‘not very confident’ or had 
‘no confidence’ with respect to their main source of hepatitis C information. However, 
nearly one-third of the sample (28%) reported that the last time they sought and received 
information it did not provide enough detail and/or explanation.  The majority (66%) 
thought that the information received did provide enough detail and/or explanation. 
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Table 3.7:  Sources of hepatitis C information and perceived credibility 
Total (N=148)
Main source of information* Used by 
  (%) 
Main source  
(%) 
Confidence in main 
source    
Leaflets/ other written material 
(excludes Hep C Review and user 
organisation magazines) 
60 24 39% ‘very confident’ 
44% ‘confident’ 
11% ‘not very confident’ 
3% ‘no confidence’ 
GP (verbal information) 45 18 58% ‘very confident’ 
27% ‘confident’ 
15% ‘not very confident’ 
User organisation publication 32 6 78% ‘very confident’ 
22% ‘confident’ 
Friends/family/partner/other 
users^ 
32 11 19% ‘very confident’ 
38% ‘confident’ 
31% ‘not very confident’ 
13% ‘no confidence’ 
Drug treatment service 24 7 64% ‘very confident’ 
27% ‘confident’ 
9% ‘not very confident’ 
NSP (verbal information) 23 9 39% ‘very confident’ 
39% ‘confident’ 
23% ‘not very confident’ 
Hep C Review 18 3 100% ‘very confident’ 
Primary health care centre 15 4 50% ‘very confident’ 
50% ‘confident’ 
Counsellor 14 3 75% ‘very confident’ 
25% ‘confident’ 
Community health centre 12 3 50% ‘very confident’ 
25% ‘confident’ 
25% ‘not very confident’ 
User Organisation (eg. NUAA) 11 2 67% ‘very confident’ 
33% ‘confident’ 
*Sources nominated by less than 10 participants not shown 
^Excludes friends/family/partner/other users who were reported to be peer educators 
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3.13 Quality of life 
Complete IDUQOL data were obtained for 104 participants.  The mean initial QOL 
rating (how would you rate your quality of life on a scale of 0–10) was 5.4 (SD 2.2), and 
the final QOL rating was 5.9 (SD 2.2).  The mean difference was 0.51, which was 
significant (t103 = 3.12, p=0.002), indicating a small, but statistically significant, increase in 
participants’ perception of their quality of life at completion of interview.  
 
The most commonly selected life area cards among this sample were family, health, 
housing, money and partnerships (Table 3.8).  There were no differences between males 
and females in the life area cards selected.  The two younger age groups (< 30 and 30– 39 
years) were more likely to choose family compared to the 40 year old and over age group 
(72% and 62%, respectively vs. 41%, χ2 = 6.08, df = 2, p=0.048). 
 
Only eight participants (8%) selected the hepatitis C life area card.  All of these eight 
participants believed they had hepatitis C, two-thirds of who were male and of various 
ages (mean 33.8 years, range 23– 46). 
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Table 3.8: Life areas determining participants’ current quality of life 
   Total (N=104) 
Life area Number of 
participants selecting 
the life area (%) 
Mean Weighting 
(SD)* 
Mean Rating 
of life area 
(SD) 
Family 61 (59) 6.9 (2.6) 56.8 (29.0) 
Health 55 (53) 5.5 (2.0) 57.8 (26.4) 
Housing 53 (51) 5.4 (2.2) 52.9 (33.5) 
Money 49 (47) 4.6 (2.6) 38.7 (27.9) 
Partnership 47 (45) 5.3 (2.1) 50.4 (32.3) 
Feeling good 37 (36) 5.3 (3.4) 46.3 (27.8) 
Friends 33 (32) 4.6 (1.3) 58.8 (26.1) 
Drug treatment 32 (31) 4.6 (2.1) 53.1 (29.5) 
Drugs 31 (30) 4.1 (2.5) 47.6 (32.8) 
Spirituality 21 (20) 4.3 (1.9) 47.4 (37.6) 
Independence 19 (18) 3.1 (1.9) 55.9 (34.3) 
Education 16 (15) 4.4 (1.6) 45.9 (30.3) 
Being useful 16 (15) 4.5 (3.2) 46.9 (25.7) 
Leisure activities 15 (14) 4.1 (1.4) 50.4 (33.9) 
Resources 13 (13) 4.2 (1.4) 73.4 (23.4) 
Sex 9 (9) 4.7 (4.3) 77.8 (22.8) 
Hepatitis C 8 (8) 4.6 (1.4) 51.9 (32.6) 
*Weighting out of a possible 25 
 
The mean global IDUQOL score was 54.2 (SD 21.2).  Differences between global 
IDUQOL scores, demographics and hepatitis C status are presented in Table 3.9.  There 
were no differences in global IDUQOL for any of the variables examined. Although not 
significantly different, those who believed themselves to have hepatitis C had a slightly 
higher global IDUQOL score than those who did not (54.9 vs. 51.6; Table 3.9).   
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Table 3.9: Global IDUQOL scores by demographics and hepatitis C status  
Variable n Mean IDUQOL (SD) 
Gendera 
 Males 
 Females 
 Transgender 
 
65 
37 
1 
 
52.8 (20.8) 
55.5 (22.1) 
69.6 (n/a) 
Age 
 ≤30 years 
 31-39 years 
 ≥40 years 
 
33 
42 
29 
 
54.8 (23.2) 
53.0 (20.2) 
55.2 (21.0) 
ATSI 
 ATSI 
 Other 
 
20 
84 
 
46.0 (23.5) 
56.1 (20.3) 
Education 
 <11 years 
 ≥11 years   
 
48 
56 
 
51.7 (21.5) 
56.4 (20.9) 
Employment 
 Employed or otherwiseb 
 Unemployed/pension 
 
16 
88 
 
48.7 (21.6) 
55.2 (21.1) 
Currently in drug treatment  
 Yes 
 No 
 
64 
40 
 
55.3 (20.5) 
52.5 (22.5) 
Hepatitis C positivec  
 Yes 
 No 
 
80 
19 
 
 
54.9 (21.5) 
51.6 (21.8) 
 
a1 case missing 
bIncludes full-time, part-time, casual, students and home duties 
c5 cases missing 
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4 DISCUSSION 
4.1 Main findings 
The current study found that a substantial proportion of IDUs hold serious 
misconceptions about hepatitis C, one of the most disturbing being that some people are 
immune to the virus, a viewpoint held by over a third of the sample.   
 
Not surprisingly, therefore, many of the participants’ understanding of their own 
hepatitis C infection was similarly confused, with one in five participants who reported 
having hepatitis C under the impression that they could not infect others and/or were 
immune to hepatitis C.  Among those who stated they had hepatitis C, nearly a third also 
stated they did not have antibodies for hepatitis C, and even more were unsure as to 
whether or not they had antibodies.  Indeed, there appeared to be substantial 
misunderstanding of the clinical term ‘antibodies’, with a large proportion of the sample 
believing that antibodies to hepatitis C protected against hepatitis C infection.  Unlike 
many other viruses, the development of antibodies against HCV does not produce 
immunity to the virus, so this is an understandable error, but of great concern 
nonetheless. 
 
Participants’ knowledge of aspects of the hepatitis C virus was often found to be 
uncertain or incorrect with respect to transmission risks, symptoms, clinical markers and 
treatment.  Many IDUs believed it was possible to catch hepatitis C by re-using their own 
needle, or from dirt, suggesting IDUs may be associating transmission with unhygienic 
practices and possibly confusing health education messages with other infections.  There 
was confusion over the symptoms of hepatitis C infection and the differences between 
various forms of hepatitis virus.  Jaundice was mistakenly thought to always be associated 
with hepatitis C by one quarter of the sample, and participants reported having a “mild” 
or “moderate” case of hepatitis C based on their subjective assessment of symptoms.     
 
Despite recent, and often multiple testing, many participants did not know the results of 
these tests, and/or misunderstood their meaning, suggesting communication of hepatitis 
C testing and diagnosis among IDUs needs to be improved.  Only about 40% of those 
tested during or after 2000 reported receiving pre- and post-test counselling.   
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The research also found that very few participants prioritise hepatitis C highly relative to 
other life areas.  However, health was frequently selected as one of the most important 
life areas determining quality of life, which is likely to incorporate symptoms and 
sequelae resulting from hepatitis C impacting on day-to-day life. 
    
4.2 Risk behaviours 
Sixteen participants (11%) reported sharing a needle or syringe in the preceding month, 
which is less than the 2004 national NSP survey where 18% of participants had used a 
needle or syringe after another person in the last month (National Centre in HIV 
Epidemiology and Clinical Research, 2005).  Nevertheless, it is consistent with an overall 
reduction in the prevalence of needle sharing in Australia (Crofts et al., 1996; Crofts & 
Aitken, 1997; MacDonald et al., 2000).  IDUs may be less cognisant of the dangers of 
sharing injecting paraphernalia other than needles however, as the prevalence of this 
practice, most notably the sharing of spoons (40%), drug solution (35%) and water 
(33%), was high.  Other Australian studies have shown that many IDUs continue to 
engage in a range of putative risk practices for hepatitis C transmission, such as the 
shared use of injecting equipment other than needles and syringes and activities that 
would promote blood spread to surfaces and other people via hands and fingers (Maher 
et al., 1998; Dwyer et al., 2002).   
 
4.3 Hepatitis C testing experience and understanding 
The vast majority of the sample reported that they had been tested for BBVI, and most 
had undergone one or more different test for hepatitis C in the past 12 months.  This is 
consistent with other research showing a high level of hepatitis C testing among heroin 
users (Day & Dolan, 2006).  This finding suggests many IDUs are aware of the risk of 
acquiring hepatitis C and are thus being tested.  It also indicates health care providers are 
testing IDUs, presumably because they are aware of the benefits of such testing.  
However, that many IDUs did not know the results of these tests, and/or misunderstood 
their meaning and implications, suggests communication of hepatitis C testing and 
diagnosis could be improved.  Moreover, such misunderstanding reduces associated 
benefits and possibly exacerbates harm. Treatments for hepatitis C remain limited and a 
range of barriers exist to prevent IDUs from accessing such treatment (Doab et al., 2005; 
Stoove et al., 2005). These results suggest that although testing and surveillance of 
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hepatitis C is widespread, support following diagnosis (or indeed a negative result) is 
limited. 
 
Although most of the IDUs were able to report the results of their recent hepatitis C 
antibody test, a number were confused about the meaning of the diagnosis (see section 
3.11).  The extract from open ended responses, “I’m not sure….I have the virus?” 
summarises the uncertainty that often accompanied a hepatitis C diagnosis.  Substantial 
numbers of IDUs reported they did not know and/or understand the results of their 
recent ALT/LFT and PCR test.  Findings such as these raise questions about patient 
involvement in health care and about how knowledge about hepatitis C and antibody 
status can be better imparted to IDUs.  In the current study, only about 40% of those 
tested during or after 2000 reported receiving pre- and post-test counselling.  The lack of 
adequate hepatitis C pre- and post-test counselling has been described in other research 
(Gifford et al., 2001; Loxley et al., 2000; Gifford et al., 2003).  Pre- and post-test 
counselling is necessary for a range of reasons, including prevention of further hepatitis 
C transmission to other users, if testing positive, or to assist in preventing infection if 
testing negative.  It appears the messages used by clinicians in providing a diagnosis and 
to describe the infectivity of the virus need to be simplified, as has been recommended 
by others (Southgate et al., 2003).  One potential strategy may be to provide IDUs with 
standardised, written results presented in a simple, easy to understand format.    
 
Testing for blood-borne viruses provides an opportunity for IDUs to access information 
and referral.  As has been noted previously (Hopwood & Treloar, 2003), the data suggest 
that a continued effort by general practitioners is needed to provide IDUs with 
comprehensive information about hepatitis C at diagnosis, and to refer to key agencies 
that provide information and support, such as the Hepatitis C Council and the Hep C 
Helpline. 
  
It is also of interest that close to half the sample reported not being vaccinated against 
HBV. This figure is consistent with serological studies (Anderson et al., 1994; 
MacDonald et al., 2004), despite self-report being a less than ideal measure of vaccination 
coverage.  IDUs remain a key target group for HBV vaccination (Heron & Campbell-
Lloyd, 2000) and more effort is required to increase vaccination knowledge and coverage.    
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4.4 Hepatitis C understanding 
The high proportion of participants reporting to have hepatitis C (76%) in this study is 
consistent with findings from the national NSP survey and other studies of IDUs 
(National Centre in HIV Epidemiology and Clinical Research, 2005; Day, 2003).  
However, many participants’ understanding of their hepatitis C infection and its 
implications appeared confused.  In line with the findings of a smaller qualitative study 
by Southgate et al. (2005), there appeared to be substantial misunderstanding of the 
clinical term ‘antibodies’, with almost one-third of those who stated they had hepatitis C 
also stating they did not have antibodies for hepatitis C (28%).  A further forty percent of 
participants reporting to have hepatitis C were uncertain about whether or not they had 
antibodies.   
 
Misunderstanding of the term ‘antibodies’ may explain why a substantial proportion of 
participants in the current study believed they could not infect others and/or were 
immune to hepatitis C (see section 4.5.2 for further discussion).  Specifically, a third of 
those who reported they had hepatitis C believed they could not pass on the virus (19%), 
or were unsure if they could (13%).  Just as disconcerting, over a third believed they were 
immune to hepatitis C (19%) or were uncertain about their immunity (23%).  It appears a 
substantial proportion of IDUs hold serious misconceptions about their hepatitis C 
infection, leaving them vulnerable to re-infection and superinfection, and at risk of 
infecting others.  In line with the recommendations by Southgate et al. (2005), these 
findings suggest that prevention efforts need to be broadened beyond messages of 
transmission risks to include education about the fundamentals of the hepatitis C virus 
itself and the meaning of antibodies in particular. These data also suggest that greater 
standardisation of the way in which test results are delivered may be needed and that less 
clinical jargon should be used when relaying test results. These results also highlight the 
need for thorough testing, including PCR testing for all antibody positive tests.  
                              
4.5 Hepatitis C knowledge 
4.5.1 Risks of transmission 
Participants’ knowledge about transmission risks for hepatitis C was characterised by 
confusion and uncertainty.  Other than knowing that injecting drugs carried a high risk of 
hepatitis C transmission, participants were confused about nearly every other mode of 
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transmission assessed (see Table 3.6).  Nearly half of the sample (48%) believed it was 
possible to infect one’s self with hepatitis C by re-using their own needle (i.e. not used by 
another), suggesting some participants may be associating transmission with unhygienic 
practices.  As reported by Southgate et al. (2005), some IDUs may not view the hepatitis 
C virus as an agent, external to the self and acquired from other people, but rather as the 
result of the unhygienic practice of re-using one’s own needle.  In this understanding, 
one’s own blood, once lodged in a used syringe, is capable of generating hepatitis C as it 
changes or, as reported by Southgate et al. (2005), it “goes off”.  The misconception of 
the risk involved in re-using one’s own needle may be the result of confusion around 
equipment disinfection—although the exact level of risk remains unclear, hepatitis C 
infection is less amenable than HIV to conventional sterilisation techniques using bleach 
(Hagan & Thiede, 2003).    
 
Similarly, over one-third of participants thought it was possible, or were unsure whether, 
hepatitis C could be acquired from dirt.  This misconception may stem from IDUs re-
interpreting public health hygiene messages that refer to the benefits of hand-washing 
and wiping surfaces after injecting to prevent the inadvertent spread of hepatitis C, rather 
than be a literal reference to the virus living in soil (Southgate et al., 2005).   
      
In general, IDUs’ perception of the risk of hepatitis C transmission associated with non-
parenteral activities appeared inflated, with the majority believing sharing household 
items such as toothbrushes or razors and unprotected sex with hepatitis C positive 
persons were high risk activities, when in fact, they are not.  Importantly, however, the 
IDUs in the current study were aware that injecting carried a high risk of hepatitis C 
transmission, and as stated previously, rates of needle-sharing were low.  Still, it is not 
clear whether or not the majority of participants knew exactly why needle-sharing is high 
risk, or whether they possessed a clear awareness of the risk of transmission through 
contaminated blood.  That substantial proportions of the IDUs interviewed had recently 
used injecting equipment after another person, most notably spoons and drug 
solution/mix, further suggests knowledge of the blood-to-blood transmission of hepatitis 
C could be improved. 
    
IDUs need to have the knowledge to reduce their risk of hepatitis transmission, most 
notably by reducing contact with blood and all manner of paraphernalia sharing.  
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Targeted and accessible education and health promotion messages may be required to 
address the confusion between hygiene and blood awareness messages.      
 
4.5.2 Clinical markers  
Participants fared somewhat better in terms of their knowledge of many of the clinical 
markers associated with hepatitis C, with over two-thirds of participants answering most 
items correctly.  For instance, the majority of participants were aware that there is more 
than one strain of hepatitis C (85%), and that once cleared, hepatitis C can be acquired 
again (75%).  Evidently, some messages are being understood better than others.   
 
However, participants’ confusion surrounding the concept of ‘antibodies’ was again 
apparent.   In qualitative research by Southgate et al. (2005) it was noted some IDUs 
were using the clinical term ‘antibodies’ to describe having a resistance to hepatitis C, 
somewhat like acquiring antibodies after having hepatitis B or common childhood 
infections such as chicken pox.   In this study, well over one-third of the IDUs agreed 
with the statement “antibodies to hepatitis C give you protection against contracting the 
virus”.  Evidently, some IDUs are under the false impression they are protected from 
acquiring hepatitis C through the presence of antibodies.  The misinterpretation of 
antibodies could also be related to confusion over the different hepatitis viruses, in 
particular hepatitis B, which is also prevalent among IDUs and for which having 
antibodies often infers immunity.  Indeed, over one-third of participants in the current 
study believed that some people are immune to hepatitis C (35%).   Clearly, there is a 
need to clarify the meaning of the term ‘antibodies’ as it pertains to hepatitis C at 
diagnosis and to debunk misconceptions of their protective effect.   
 
As reported previously (Rhodes et al., 2004; Southgate et al., 2003; Southgate et al., 
2005), a number of IDUs were confused over the differences between various forms of 
hepatitis virus and the symptoms of hepatitis C.  Over one quarter of the participants in 
the current study believed incorrectly that hepatitis C was always associated with jaundice 
(26%).  The belief that hepatitis C status can be determined by the symptom of jaundice 
has prevention implications, as some IDUs may assume they do not have hepatitis C and 
that it is safe to share injecting equipment.  IDUs should be informed that jaundice is not 
a reliable sign for gauging either infection or infectiousness.  In addition, they should be 
advised not to wait for signs of jaundice, or any other sign, before being tested for 
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hepatitis C.  In this study, approximately one-third of participants reported they had 
experienced signs of hepatitis C infection prior to testing, most notably lethargy and 
feeling unwell.  Unlike hepatitis A and B, most (~80%) people do not experience 
symptoms during the initial (acute) phase of hepatitis C infection, and need to be 
informed as such.  Many participants also reported having a “mild” or “moderate” case 
of hepatitis C based on their symptoms.  The often asymptomatic nature of hepatitis C 
should be emphasised so that IDUs do not attempt to determine their status based on 
their symptoms, or lack thereof.   
 
4.5.3 Treatment 
As has been found previously (Doab et al., 2005), there is a poor understanding of 
treatment among IDUs.   Although most IDUs knew that there was treatment available 
for hepatitis C, substantial proportions were confused about herbal remedies.  They also, 
often wrongly, believed that it was still possible to pass on the virus following successful 
Interferon/Ribavirin treatment, which indicates many are unaware of curative potential 
of treatment and may reflect a lack of knowledge about treatment in general.  Previous 
research has found that many IDUs believe that being a current IDU is an exclusion 
criterion for treatment, and recommended targeted education initiatives be used to 
improve understanding of the treatments available and access to treatment (Doab et al., 
2005). 
   
4.6 Quality of life 
The global IDUQOL score in this study was 54.2.  This score is similar to that of a 
sample of Canadian IDUs recruited in major cities and drug markets (Brogly et al., 
2003b), as well as small samples of Australian IDUs, who scored a mean of 47.5 (Kimber 
& Day, 2003) and 53.9 (Day et al., 2005).  
 
Hepatitis C was selected by only eight percent of participants as an area that most 
determined their quality of life, making it the least frequently chosen life area in the 
study.  However, many participants selected health as an area of importance, upon which 
hepatitis C may well impact.  Two-thirds of participants reported that their family was 
among the five life areas they believed most determined their quality of life at the time of 
interview (62%).  The other life areas chosen by more than half of participants were 
health (55%) and housing (52%).  These findings provide an insight into the life areas 
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perceived as the most meaningful in determining the participants’ quality of life.  It is 
possible that hepatitis C infection may simply be a low priority compared with issues 
concerning relationships, housing, and other non-hepatitis C related health issues. 
 
Although not significant, those who believed themselves to be hepatitis C positive had a 
slightly higher global IDUQOL score than those who did not (54.9 vs. 51.6; Table 3.8).  
This unexpected relationship has been noted in previous research (Day et al., 2005); 
although in subsequent multivariate analysis the relationship did not persist. The 
IDUQOL, however, is a global measure of quality of life and the lack of relationship 
with hepatitis C may reflect the lack of centrality of hepatitis C in IDUs’ lives, especially 
given the often asymptomatic nature and protracted natural history of hepatitis C and its 
prevalence among IDUs (MacDonald et al., 2000).  Participant numbers in the current 
study were considered insufficient for further analysis. More recent investigation of 
IDUs’ QOL has been complemented by the use of a general population health status 
measure to allow comparison and discussion with the broader literature (O'Brien et al., in 
press).   
 
4.7 Limitations 
There are a number of limitations of the study.  The study relied on a convenience 
sample of IDUs recruited primarily through NSPs and methadone clinics, who may not 
be representative of the broader IDU population who do not attend such health services.  
IDUs are a hidden population and it is not possible to obtain a random sample.  
However, a range of recruitment strategies were utilised, and sample characteristics and 
drug use were similar to other samples of IDUs.  The sample included participants 
recruited from multiple sites (inner-city, suburban and regional areas), who were both in 
and out of drug treatment at the time of interview.    
 
Due to largely ethical and practical considerations, this study did not review clinical 
records to confirm serology, limiting the study’s ability to accurately determine the 
prevalence of infection among the sample.  However, the relatively high proportion of 
people reporting to be hepatitis C positive is consistent with other research examining 
the prevalence of hepatitis C among IDUs (Day, 2003).  Furthermore, serology is less 
important in the case of determining IDUs’ understanding and beliefs of hepatitis C, as 
was the aim of the current study. 
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Also, as with all interviewer administered surveys, socially desirable response bias may 
influence the data.  However, studies have found that IDUs are no more likely than any 
other population to report erroneously about themselves or their behaviours, especially 
when recall periods are kept short (Goldstein et al., 1995). Social desirability is most likely 
to have impacted on reports of risk behaviour, which has recently been shown to be 
reported less frequently in interviewer administered questionnaires compared to self-
completed instruments (White et al., in press).  
 
Finally, it is possible that participants may have been confused about some of the 
true/false statements, concerning the relative risks of hepatitis C transmission in 
particular.  Extensive piloting of the questionnaire was conducted and attempts made to 
address any confusing items.  Further, the qualifiers of ‘no risk’, ‘low risk’ and ‘high risk’ 
were explained thoroughly to participants at the time of interview.  Nonetheless, 
interviewers noted a degree of confusion over some of these items, and future research 
may consider simplifying the items further.    
 
4.8 Conclusions 
The study uncovered a number of fundamental misconceptions among IDUs about 
hepatitis C in terms of transmission, symptoms, clinical markers and treatment.  Many 
IDUs were misinformed about hepatitis C transmission, particularly the risks associated 
with the re-use of one’s own injecting equipment and unprotected sex.  Of major 
concern is the misunderstanding of the term ‘antibodies’ among IDUs and their 
perceived role in providing immunity.    
   
One in five IDUs who stated they had hepatitis C in the current study believed they 
could not infect others, and just as many believed they were immune.  About one in 
three participants stated they did not have antibodies for hepatitis C, and even more were 
uncertain, despite reporting themselves to have hepatitis C.     
 
Despite recent, and often multiple testing, many IDUs did not know the results of these 
tests, and/or misunderstood their meaning, suggesting communication of hepatitis C 
testing and diagnosis among IDUs needs to be improved. Only about 40% of those 
tested during or after 2000 reported receiving pre- and post-test counselling.    
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The study also found that although rates of needle-sharing were low, many IDUs 
continue to share other injecting equipment.  The use of injecting equipment after 
another person was quite common with 40% sharing spoons, 35% the drug solution or 
mix, and 33% water in the past month. 
 
Given the high prevalence and incidence of hepatitis C among Australian IDUs, and that 
many continue to share injecting equipment, the findings of this study are of great 
concern.  The misconceptions about hepatitis C leave IDUs vulnerable to infection, and 
at risk of infecting others.  IDUs need to have the knowledge to reduce their risk of 
hepatitis transmission.  As recommended by Southgate et al. (2003), there is an urgent 
need to simplify, standardise and clarify the language and education messages around 
hepatitis C for IDUs, clinicians and other health workers to reduce this confusion.  The 
meaning of the term ‘antibodies’ as it pertains to hepatitis C needs to be clarified for 
IDUs and misconceptions of their protective effect corrected.  The erroneous belief that 
some individuals are immune to hepatitis C also needs to be specifically addressed.                            
 
The messages used by clinicians in providing a diagnosis and to describe the infectivity of 
hepatitis C need to be examined and simplified as well, as evidenced by the confusion 
surrounding test results. Providing IDUs with written results presented in a standardised, 
uncomplicated format to take with them may be a strategy worth exploring.  Further 
research could focus on innovative education strategies to improve IDUs’ understanding 
of hepatitis C status, re-infection, super-infection and the ability to infect others, as well 
as ways in which pre- and post-test counselling might be improved.   
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